BiotechTubeBiotechTube
Home/Exelixis/Michael M. Morrissey
MM

Michael M. Morrissey

President and Chief Executive Officer

Exelixis

Therapeutic Areas

OncologyRenal Cell CarcinomaColorectal CancerNeuroendocrine TumorsMultiple Solid Tumors

Exelixis Pipeline

DrugIndicationPhase
CabozantinibAdvanced Renal Cell CarcinomaPhase 3
Zanzalintinib + atezolizumabMetastatic Colorectal CancerPhase 3
Zanzalintinib + nivolumabNon-Clear Cell Renal Cell CarcinomaPhase 3
ZanzalintinibNeuroendocrine TumorsPhase 2/3
Zanzalintinib + belzutifanRenal Cell CarcinomaPhase 3
XL309Multiple Solid TumorsPhase 1
XB010Multiple Solid TumorsPhase 1
XB628Multiple Solid TumorsPhase 1

Leadership Team at Exelixis

DT
Dana T. Aftab
Executive Vice President, Research and Development
CJ
Christopher J. Senner
Executive Vice President and Chief Financial Officer
BJ
Brenda J. Hefti
Senior Vice President and General Counsel
PH
P.J. Haley
Executive Vice President, Commercial
SP
Stelios Papadopoulos
Chair of the Board
MC
Mary C. Beckerle
Director
SG
S. Gail Eckhardt
Director
MC
Maria C. Freire
Director
T(
Tomas (Tom) J. Heyman
Director
DE
David E. Johnson
Director
View full Exelixis profile